Concerto HealthAI entered into a multi-disease collaboration with Janssen Research & Development, LLC. Known for their market-leading enterprise AI technology solutions leveraging Real-World Data (RWD) for Precision Oncology, Concerto HealthAI offers Janssen the opportunity to use their innovative solutions and scientific services.
Jeff Elton, PhD, Concerto HealthAI’s CEO, spoke about the partnership, saying that, “We believe our mission and responsibility as a leader in Precision Oncology aligns well with Janssen’s innovation focus in data science. We are excited to bring our unique integration of RWD, technology applications, and data science expertise to collaborate with Janssen’s researchers and data scientists to optimize drug development for patients.”
Thanks to Concerto HealthAI’s licensing agreement with the American Society of Clinical Oncology’s CancerLinQ® program, their products exist on the cutting edge of their field. Janssen has access to a plethora of these programs under Concerto HealthAI’s eurekaHealth 3.0 enterprise AI solution. The solution pulls and enriches multiple sources in order to offer a holistic view of patient journeys. It also serves as an intelligence layer, smoothly integrating into clinical and research development workflows anywhere in an enterprise.
As part of the partnership Janssen also gains exclusive access to Genome360™. Currently in development, this real-world solution integrates next-generation sequencing characterization of a patient’s cancer to provide clinical insights with broad coverage for sequencing mutations.
